Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,Toxicology
Reference47 articles.
1. Arlett P, Portier G, de Lisae R, Blake K, Wathion N, Dogne JM, et al. Proactively managing the risk of marketed drugs: experience with the EMA Pharmacovigilance Risk Assessment Committee. Nat Rev Drug Discov. 2014;13:395–7.
2. European Medicines Agency. Guideline on good pharmacovigilance practices (GVP). Module IX: signal management (Rev 1). 2017; EMA/827661/2011 Rev 1. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-gvp-module-ix-signal-management-rev-1_en.pdf. Accessed Sep 2019.
3. Vora P, Artime E, Soriano-Gabarró M, Qizilbash N, Singh V, Asiimwe A. A review of studies evaluating the effectiveness of risk minimisation measures in Europe using the European Union electronic register of post-authorization studies. Pharmacoepidemiol Drug Saf. 2018;27:695–706.
4. Mol PGM, Straus SMJM, Piening S, de Vries JTN, de Graeff PA, Haaijer-Ruskamp FM. A decade of safety-regulated regulatory action in The Netherlands. Drug Saf. 2010;33:463–74.
5. Piening S, Haaijer-Ruskamp FM, de Vries JTN, van der Elst ME, de Graeff PA, Straus SMJM, et al. Impact of safety-related regulatory action on clinical practice. Drug Saf. 2012;35:373–85.
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献